Pre-clinical and clinical data have highlighted the benefit of targeting the TGF beta pathway to reduce the cardiac fibrosis [5] and the key role of the TGF beta-CCN2/CTGF axis [6]. The gene discussed is CCN2; the disease is fibrosis.